N-glycolylneuraminic acid serum biomarker levels are elevated in breast cancer patients at all stages of disease
Abstract
Normal human tissues do not express glycans terminating with the sialic acid N-glycolylneuraminic acid (Neu5Gc), yet Neu5Gc-containing glycans have been consistently found in human tumor tissues, cells and secretions and have been proposed as a cancer biomarker. We engineered a Neu5Gc-specific lectin called SubB2M, and previously reported elevated Neu5Gc biomarkers in serum from ovarian cancer patients using a Surface Plasmon Resonance (SPR)-based assay. Here we report an optimized SubB2M SPR-based assay and use this new assay to analyse sera from breast cancer patients for Neu5Gc levels.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 26, 2022
- Source ID
- 10.1186/s12885-022-09428-0
Entities
People
- Adrienne W. Paton
- Christopher J. Day
- Colleen Niland
- James C. Paton
- Jamie R. Kutasovic
- Jessica Poole
- Jing Wang
- Jodi M Saunus
- Jodie L. Abrahams
- Kaltin Ferguson
- Lucy K. Shewell
- Mark Von Itzstein
- Michael P. Jennings
- Sunil R. Lakhani
Organizations
- National Health and Medical Research Council
- Royal Brisbane and Women's Hospital Foundation
- United States Department of Defense